A study suggests semaglutide could reduce heart attack risk by 20%, independent of weight loss. It involved 17,604 adults globally. Participants taking semaglutide had fewer cardiovascular events compared to the placebo group.
Semaglutide, known as Wegovy, is prescribed for weight loss in the UK. Prof. John Deanfield sees semaglutide as groundbreaking for cardiovascular health.
He compares its impact to statins in the 1990s. The medication could transform chronic diseases, says Deanfield. Prof. Jason Halford predicts a radical shift in healthcare.
He anticipates significant cost savings and productivity boosts. About 7.6 million UK citizens suffer from heart or circulatory diseases.
Another study suggests a new injection, Retatrutide, is more effective for weight loss. Researchers report a 24% reduction in body weight over 48 weeks. Prof. Naveed Sattar believes Retatrutide could achieve further weight loss. The trial indicates Retatrutide’s potential to surpass existing weight loss treatments.